<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23508" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Inflammatory Back Pain</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lassiter</surname>
            <given-names>William</given-names>
          </name>
          <aff>San Antonio Uniformed Services</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhutta</surname>
            <given-names>Beenish S.</given-names>
          </name>
          <aff>Sheikh Zayed Hospital, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Allam</surname>
            <given-names>Abdallah E.</given-names>
          </name>
          <aff>Tanta University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>William Lassiter declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Beenish Bhutta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdallah Allam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23508.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Inflammatory back pain (IBP) is chronic pain&#x000a0;concentrated&#x000a0;in the&#x000a0;axial spine and sacroiliac joints,&#x000a0;distinguishing it from mechanical back pain&#x000a0;through specific diagnostic features. While strongly&#x000a0;linked&#x000a0;to inflammatory conditions,&#x000a0;IBP is not diagnostic.&#x000a0;IBP is a hallmark symptom of spondyloarthritis, characterized by insidious onset, morning stiffness, and improvement with exercise but not rest. Clinicians must recognize these distinctive features for early diagnosis and appropriate management.</p>
        <p>This course discusses the association of IBP with ankylosing spondylitis and other seronegative spondyloarthropathies, including psoriatic arthritis, enteropathic arthropathy, juvenile idiopathic arthritis, and reactive arthritis. Patient characteristics, chronicity, and pain progression are also discussed, offering clinicians valuable insights to differentiate IBP from other causes and emphasizing a comprehensive approach to address the complexities of this complex pain syndrome associated with&#x000a0;spondyloarthritis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;diagnostic features of inflammatory back pain to enable accurate differentiation from mechanical back pain.</p></list-item><list-item><p>Screen for inflammatory back pain risk factors, including age, chronicity, and specific pain patterns.</p></list-item><list-item><p>Implement multimodal treatment approaches.</p></list-item><list-item><p>Communicate effectively with patients undergoing treatment for inflammatory back pain.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23508&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23508">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23508.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Inflammatory back pain (IBP) is chronic pain&#x000a0;concentrated&#x000a0;in the&#x000a0;axial spine and sacroiliac joints,&#x000a0;distinguishing it from mechanical back pain&#x000a0;through specific diagnostic features. While strongly&#x000a0;linked&#x000a0;to inflammatory conditions,&#x000a0;IBP is not diagnostic.&#x000a0;</p>
        <p>Several key characteristics help differentiate IBP from other causes of back pain:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Localization of pain:</bold> IBP&#x000a0;is typically localized on the axial spine, particularly the lumbar spine. Additionally, patients may experience alternating buttock pain from one side to another.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Patient characteristics:</bold> The patient's characteristics, such as age and chronic pain, are crucial in distinguishing IBP. Associated with the onset of pain before the age of 40, persistent pain&#x000a0;lasts for 3 months or more.<xref ref-type="bibr" rid="article-23508.r1">[1]</xref><xref ref-type="bibr" rid="article-23508.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pain progression:</bold> The progression of pain over time is another important factor in diagnosing IBP. The pain often follows an insidious course, gradually worsening over an extended period.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Morning Stiffness:</bold> Patients with IBP commonly experience morning stiffness, which tends to improve with movement or exercise. This significant feature helps differentiate it from&#x000a0;other forms of back pain.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Association with inflammatory conditions:</bold> While the classic association&#x000a0;is with ankylosing spondylitis, IBP may also be present in other seronegative spondyloarthropathies such as psoriatic arthritis (PsA), enteropathic arthropathy, juvenile idiopathic arthritis (RIA), and reactive arthritis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Undifferentiated causes:</bold> In some cases, the cause of IBP may be undifferentiated, given the absence or combination of diagnostic features of any of these conditions.<xref ref-type="bibr" rid="article-23508.r3">[3]</xref><xref ref-type="bibr" rid="article-23508.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23508.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The identification of seronegative spondyloarthropathies&#x000a0;often follows the presentation of IBP. The etiology of these conditions is complex, typically linked to a systemic inflammatory response&#x000a0;triggered by a known or unknown source. This systemic inflammation induces local tissue alterations that&#x000a0;may persist in the joint environment. The persistence of inflammation, mediated by pathways like interleukin-17 (IL-17) and tumor necrosis factor (TNF), contributes to an ongoing cycle of imbalanced bone remodeling, leading to axial bone loss.<xref ref-type="bibr" rid="article-23508.r2">[2]</xref></p>
        <p>The inflammatory&#x000a0;changes and subsequent structural alterations, classically observed in imaging through vertebral bone fusion in conditions like ankylosing spondylitis,&#x000a0;provide insight into the insidious onset of chronic pain observed in patients with IBP. These manifestations have been pivotal in directing research toward potential intervention strategies.<xref ref-type="bibr" rid="article-23508.r1">[1]</xref><xref ref-type="bibr" rid="article-23508.r5">[5]</xref></p>
      </sec>
      <sec id="article-23508.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The assessment of IBP&#x000a0;prevalence in the US for adults aged 20 to 69 is&#x000a0;approximately 5% to 6%.<xref ref-type="bibr" rid="article-23508.r6">[6]</xref> However, a&#x000a0;gap exists between the prevalence of IBP and a relatively lower prevalence of spondyloarthropathies in the US,&#x000a0;ranging from only&#x000a0;0.9% to 1.4%. Studies conducted in Asia&#x000a0;reveal an even lower incidence of ankylosing spondylitis in that population, near 0.001%. Further, only 36% of Asian populations&#x000a0;experiencing&#x000a0;IBP meet the criteria for spondyloarthropathy.<xref ref-type="bibr" rid="article-23508.r7">[7]</xref>&#x000a0;This gap between the prevalence of IBP and seronegative spondyloarthropathy has&#x000a0;prompted some researchers to explore&#x000a0;other potential causes or&#x000a0;propose that&#x000a0;IBP may be distinct&#x000a0;from other inflammatory immune-mediated conditions.</p>
        <p>A&#x000a0;UK study&#x000a0;observed&#x000a0;a minimum prevalence of IBP&#x000a0;ranging from 1.7% to 3.4% in primary care.<xref ref-type="bibr" rid="article-23508.r6">[6]</xref>&#x000a0;Similarly, a study conducted&#x000a0;in Mexico&#x000a0;reported&#x000a0;a prevalence of 3% for IBP in that population.<xref ref-type="bibr" rid="article-23508.r6">[6]</xref> Notably, the frequency of IBP in different populations varies considerably depending on the diagnostic criteria employed; however, in most studies, the prevalence does not exceed 8%.</p>
        <p>In at least 1 large study, IBP was found to be more prevalent among non-Hispanic white individuals than non-Hispanic black&#x000a0;individuals&#x000a0;(5.9% versus&#x000a0;3.3%).&#x000a0;Limited evidence currently supports the existence of a significant difference in IBP rates based on gender or age group.<xref ref-type="bibr" rid="article-23508.r8">[8]</xref></p>
      </sec>
      <sec id="article-23508.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>IBP&#x000a0;is a chronic pain condition characterized by an insidious onset of pain localized to the lower back and buttocks.&#x000a0;The&#x000a0;pathophysiology stems from a systemic inflammatory response to&#x000a0;an insult, leading to the localization of inflammatory mediators&#x000a0;in the axial skeletal joints and&#x000a0;triggering proinflammatory intracellular changes. This&#x000a0;persistent inflammatory condition results in a cycle of unbalanced bone remodeling associated with bone loss and&#x000a0;potential for bone fusion.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Ankylosing spondylitis:</bold>&#x000a0;Ankylosing spondylitis and other forms of spondyloarthritis affect the axial skeleton, involving the interplay between bone, ligaments, tendons, and cartilage. SpA-specific gut microbiota activates innate lymphoid cells that produce proinflammatory cytokines. Inflammatory processes occurring in the entheses and joints&#x000a0;contribute to&#x000a0;bone erosion,&#x000a0;while mechanical stress&#x000a0;triggers the generation of&#x000a0;IL-17. The human leukocyte antigen (HLA) B27 gene plays a significant&#x000a0;role in several key pathogenic processes, although non-HLA genes have also been identified.<xref ref-type="bibr" rid="article-23508.r9">[9]</xref> Inflammation initiates changes in bone, leading to new bone formation, such as syndesmophytes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>PsA:</bold>&#x000a0;The cause of PsA is&#x000a0;unknown, although some factors have been suggested. Genetic factors play a role in PsA pathogenesis, as evidenced by a higher prevalence&#x000a0;within certain families and among twins and an association with specific histocompatibility antigens. Additionally, several environmental factors, including infections and trauma, have been linked to PsA. Immunologic mechanisms are&#x000a0;indicated by the shared inflammatory response observed in&#x000a0;psoriatic skin and synovial lesions and inflammation in soft tissues and the spine, features shared with axial spondyloarthritis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Enteropathic arthropathy:</bold>&#x000a0;The development of arthritis and inflammatory bowel disease (IBD) may involve the influence of gastrointestinal bacteria. For example, in a study involving rats raised in a germ-free environment and transgenic for the HLA-B27, there were&#x000a0;no reported&#x000a0;instances of&#x000a0;joint or intestinal inflammation.<xref ref-type="bibr" rid="article-23508.r10">[10]</xref> Moreover,&#x000a0;individuals with Crohn disease and ankylosing spondylitis&#x000a0;exhibited&#x000a0;increased levels of immunoglobulin M (IgM) and IgG antibodies to collagen types I, III, IV, V, and <italic toggle="yes">Klebsiella</italic>
<italic toggle="yes">pneumoniae</italic> compared to healthy controls.<xref ref-type="bibr" rid="article-23508.r11">[11]</xref>&#x000a0;Additionally, these patients&#x000a0;display a positive antibody response to <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> serotypes, a phenomenon not observed in patients with celiac disease or healthy controls.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>JIA:&#x000a0;</bold>Joint damage&#x000a0;in JIA arises from&#x000a0;the formation of inflamed synovial tissue,&#x000a0;known as pannus. This process involves synoviocyte proliferation and infiltration by inflammatory cells. Vascular factors, cytokines, adhesion molecules, and chemokines facilitate infiltration into the synovium, and inflammatory cells are also present in the synovial fluid. Consequently, the pannus&#x000a0;extends and adheres to intraarticular cartilage,&#x000a0;resulting in&#x000a0;cartilage degradation at the pannus-cartilage junctions.<xref ref-type="bibr" rid="article-23508.r12">[12]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Reactive arthritis:</bold>&#x000a0;Major causative organisms for reactive arthritis include&#x000a0;<italic toggle="yes">Campylobacter</italic>,&#x000a0;<italic toggle="yes">Salmonella</italic>, and&#x000a0;<italic toggle="yes">Shigella</italic>.<xref ref-type="bibr" rid="article-23508.r13">[13]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23508.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Though not a diagnostic criterion, IBP has been&#x000a0;established as a&#x000a0;sentinel condition for seronegative spondyloarthropathies. Histopathologic&#x000a0;studies&#x000a0;in patients with spondyloarthropathies, compared to&#x000a0;those with rheumatoid arthritis,&#x000a0;reveal&#x000a0;heightened vascularity, the proliferation of CD163+ macrophages, and increased levels of polymorphonuclear leukocytes.<xref ref-type="bibr" rid="article-23508.r14">[14]</xref>&#x000a0;The synovial membrane&#x000a0;undergoes&#x000a0;inflammation and thickening due to the infiltration of immune cells such as T cells, B cells, and macrophages. These cells release cytokines such as TNF-&#x003b1; and interleukins (IL-1, IL-6, and IL-17), exacerbating inflammation and contributing to tissue damage. In addition to synovial inflammation, IBP is&#x000a0;associated with erosion of the adjacent bone tissue.&#x000a0;This erosion results from the activation of osteoclasts, triggered by the release of cytokines such as TNF-&#x003b1; and receptor activator of nuclear factor kappa-B ligand (RANKL) by immune cells.</p>
      </sec>
      <sec id="article-23508.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>IBP&#x000a0;is differentiated from mechanical back pain by its insidious onset, alleviation&#x000a0;with exercise,&#x000a0;absence of improvement with rest, and nocturnal pain that improves&#x000a0;upon rising and movement. Its connection to&#x000a0;seronegative spondyloarthropathies suggests that an inciting illness or systemic inflammatory process might precede IBP.<xref ref-type="bibr" rid="article-23508.r3">[3]</xref></p>
      </sec>
      <sec id="article-23508.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>When distinguished from other causes of back pain using accepted diagnostic criteria,&#x000a0;IBP can&#x000a0;serve as a referral criterion for rheumatologic evaluation. This is especially pertinent when supported by a positive HLA-B27 laboratory test and sacroiliitis evident&#x000a0;in imaging studies&#x000a0;that align with the established&#x000a0;pain criteria.</p>
        <p>Up to&#x000a0;50% of patients with axial spondyloarthropathy&#x000a0;may exhibit an&#x000a0;increased acute phase response, marked by elevated erythrocyte sedimentation rate and C-reactive protein levels. However, similar elevations in these values are also typically associated with rheumatoid arthritis.<xref ref-type="bibr" rid="article-23508.r15">[15]</xref><xref ref-type="bibr" rid="article-23508.r16">[16]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Ankylosing spondylitis:</bold>&#x000a0;A positive Schober test is observed during the physical examination. This test evaluates the mobility and flexibility of the lumbar spine by marking&#x000a0;2 points on the lower back&#x02014;1&#x000a0;point 10 cm above the sacrum and the other 5 cm above the first mark. The distance between these&#x000a0;2 points is measured while the patient stands upright and again while bending forward as much as possible. A Schober test is considered positive if there is less than a 5 cm increase in distance between the&#x000a0;2 marks on the lower back when the patient bends forward.<xref ref-type="bibr" rid="article-23508.r17">[17]</xref><bold>&#x000a0;</bold>Radiographic findings of the sacroiliac (SI) joints can range from subtle joint space narrowing and sclerosis to erosive changes. Eventually, this&#x000a0;progression may lead to bony ankylosis (fusion).&#x000a0;For&#x000a0;diagnostic purposes, ankylosing spondylitis is&#x000a0;confirmed with the combination of at least&#x000a0;1 associated clinical criterion and at least&#x000a0;1 imaging criterion, meeting the severity and duration criteria for findings.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>PsA:</bold>&#x000a0;Magnetic resonance imaging (MRI) of axial&#x000a0;SI joints shows bone marrow edema in the iliac and sacral bones, sclerosis, chronic changes in periarticular fat accumulation, erosions, and new bone formation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Enteropathic arthropathy:&#x000a0;</bold>X-rays can&#x000a0;reveal joint abnormalities like swelling and bone loss,&#x000a0;although these&#x000a0;manifestations can also be present in patients without IBD symptoms.&#x000a0;MRI effectively detects joint changes but may not&#x000a0;consistently correlate with back pain. Therefore, its&#x000a0;recommendation is reserved for patients&#x000a0;exhibiting back pain and IBD symptoms.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>JIA:</bold>&#x000a0;Patients with JIA often&#x000a0;exhibit a positive antinuclear antibody (ANA), an elevated erythrocyte sedimentation rate (&#x02265;40 mm/hour), hypergammaglobulinemia, and anemia (hemoglobin concentration &#x02264;11 g/dL) may be observed.<xref ref-type="bibr" rid="article-23508.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23508.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>A referral to a rheumatologic specialist may be warranted after establishing a diagnosis of IBP using accepted criteria, particularly&#x000a0;when accompanied by&#x000a0;positive HLA-B27 testing and confirmation of sacroiliitis&#x000a0;through imaging. Timely and collaborative efforts between healthcare professionals contribute to a more effective and patient-centered approach to addressing the complexities of&#x000a0;IBP and its underlying causes.</p>
        <p>The initial treatment for IBP&#x000a0;begins with patient education&#x000a0;regarding the nature of their condition and the expected course. Patients should be informed regarding the possibility of associated conditions, prompting further investigation into underlying causes through laboratory evaluation and imaging.&#x000a0;Emphasizing the importance&#x000a0;of smoking cessation is crucial. Additionally, discussing sources of psychosocial support is essential.&#x000a0;Physical therapy consultation is often recommended, given the favorable response of IBP and its associated inflammatory&#x000a0;conditions to&#x000a0;exercise and movement therapies.</p>
        <p>The initial pharmacologic&#x000a0;approach&#x000a0;for IBP, whether&#x000a0;symptomatic of&#x000a0;axial spondyloarthropathy or not, typically involves a trial of nonsteroidal anti-inflammatory drug (NSAID) therapy,&#x000a0;often necessitating a&#x000a0;maximum dose.&#x000a0;This initial treatment should&#x000a0;span 2&#x000a0;to&#x000a0;4 weeks, during which effectiveness is evaluated. Identifying&#x000a0;an effective medication can be utilized as needed for&#x000a0;symptom control.</p>
        <p>In cases where NSAID therapy proves ineffective for symptom control in patients with known axial spondyloarthropathy, the next medications include TNF inhibitors or an alternative, such as secukinumab.<xref ref-type="bibr" rid="article-23508.r18">[18]</xref> If a patient initially responds to a TNF inhibitor but experiences a loss of efficacy, a switch to a second TNF inhibitor is recommended. However, for patients&#x000a0;intolerant to 1 or 2&#x000a0;TNF inhibitors or with an inadequate response (typically after&#x000a0;3 months of therapy for each TNF inhibitor used), it is&#x000a0;advisable&#x000a0;to switch to an anti-IL-17 antibody like ixekizumab or secukinumab or a JAK inhibitor such as tofacitinib or upadacitinib.&#x000a0;These medication classes compromise the&#x000a0;immune response, necessitating careful consideration of immune function,&#x000a0;malignancy diagnosis, heart health, or coexisting demyelinating diseases.</p>
        <p>Surgical intervention may be indicated in&#x000a0;cases of IBP with axial spondyloarthritis&#x000a0;under various circumstances, such as&#x000a0;severe hip involvement&#x000a0;causing&#x000a0;persistent pain or severe limitation in mobility and quality of life, atlantoaxial subluxation with neurologic impairment, and severe flexion deformities&#x000a0;resulting in impaired ability to&#x000a0;gaze in a forward direction.<xref ref-type="bibr" rid="article-23508.r19">[19]</xref><xref ref-type="bibr" rid="article-23508.r20">[20]</xref></p>
        <p>It is crucial to consider the unique aspects of each condition, including its progression and response to treatment, to ensure comprehensive and effective management. Please refer to separate resources for more specific information on managing individual conditions.<xref ref-type="bibr" rid="article-23508.r9">[9]</xref><xref ref-type="bibr" rid="article-23508.r12">[12]</xref><xref ref-type="bibr" rid="article-23508.r21">[21]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23508.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of&#x000a0;IBP encompasses&#x000a0;mechanical, nonmechanical, and visceral sources. It is crucial to exclude&#x000a0;pain sources&#x000a0;stemming from cancer or vertebral body compression fractures. Recall that the characteristic features of IBP&#x000a0;include&#x000a0;age of onset less than 40, back pain duration&#x000a0;exceeding&#x000a0;3 months, insidious onset, morning stiffness, and improvement with exercise. In contrast, causes of mechanical back pain&#x000a0;typically exacerbate&#x000a0;with movement and exercise and&#x000a0;often correlate with injury, presenting a more acute onset.<xref ref-type="bibr" rid="article-23508.r22">[22]</xref></p>
        <p>Patients should undergo an assessment for neurologic deficits that may&#x000a0;indicate compression of the spinal cord or cauda equina syndrome. Additionally, patients with a high clinical suspicion of vertebral osteomyelitis or epidural abscess warrant an immediate MRI.</p>
        <p>In a study&#x000a0;assessing the&#x000a0;efficacy of&#x000a0;traditionally&#x000a0;considered indicators of&#x000a0;cancer as the cause of back pain, it was discovered that a history of malignancy and strong clinical suspicion of cancer were the most&#x000a0;valuable factors&#x000a0;directing&#x000a0;the evaluation&#x000a0;toward a potential cancer-related origin of&#x000a0;back pain.<xref ref-type="bibr" rid="article-23508.r23">[23]</xref></p>
      </sec>
      <sec id="article-23508.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>NSAIDs constitute the first-line treatment for seronegative spondyloarthropathies, showcasing&#x000a0;substantial efficacy in alleviating&#x000a0;IBP. Additionally, NSAIDs have proven effective in enhancing the duration of morning stiffness and chest expansion in related arthropathies. When integrated with other demonstrated effective interventions, such as exercise and physical therapy, these medications can significantly improve&#x000a0;the overall quality of life for patients experiencing IBP.<xref ref-type="bibr" rid="article-23508.r24">[24]</xref><xref ref-type="bibr" rid="article-23508.r25">[25]</xref></p>
        <p>While&#x000a0;direct evidence linking&#x000a0;IBP&#x000a0;to increased mortality is limited, ankylosing spondylitis and other spondyloarthropathies involving the axial spine&#x000a0;are associated with&#x000a0;a 36% to 76% increased risk&#x000a0;of acute coronary syndrome (ACS) and a 50% increased risk of venous thromboembolism. Notably, female patients with PsA demonstrate&#x000a0;nearly double the risk of ACS compared to the general population. However, given the relatively young age&#x000a0;at which these diseases and associated IBP manifest, the absolute risks of ACS, venous thromboembolism, or stroke in these populations&#x000a0;remain modest.<xref ref-type="bibr" rid="article-23508.r26">[26]</xref></p>
      </sec>
      <sec id="article-23508.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The immunologically mediated process associated with IBP also correlates with a cycle of unbalanced bone remodeling, leading to osteoporosis, which becomes notable within the first 10 years of diagnosis.&#x000a0;Individuals with&#x000a0;ankylosing spondylitis face twice&#x000a0;the&#x000a0;likelihood of experiencing vertebral fractures as the general population, with extensions most commonly occurring in the cervical region.<xref ref-type="bibr" rid="article-23508.r27">[27]</xref> Spinal cord injury is 11 times more common in ankylosing spondylitis, and patients with long-standing disease are at an increased risk of cauda equine syndrome. Additionally, individuals with axial spondyloarthropathy may be at higher risk of renal disease, with an 8% increase in abnormal urinalysis than the general population.<xref ref-type="bibr" rid="article-23508.r28">[28]</xref><xref ref-type="bibr" rid="article-23508.r29">[29]</xref><xref ref-type="bibr" rid="article-23508.r30">[30]</xref></p>
        <p>The chronic&#x000a0;use of&#x000a0;NSAIDs for patients with IBP carries associations with various possible complications. NSAIDs have links&#x000a0;to the exacerbation of peptic ulcer disease, an increased risk of cardiovascular events in at-risk populations, incitement of renal injury or failure, and exacerbation of existing reactive airway disease. Initiating NSAID administration should involve careful consideration of the patient&#x02019;s underlying disease process associated with IBP, other comorbid illnesses, and&#x000a0;concurrent medications, particularly glucocorticoids, anticoagulants, diuretics, and selective serotonin reuptake inhibitors (SSRIs).<xref ref-type="bibr" rid="article-23508.r31">[31]</xref><xref ref-type="bibr" rid="article-23508.r32">[32]</xref></p>
      </sec>
      <sec id="article-23508.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>After confirming&#x000a0;the diagnosis of&#x000a0;IBP&#x000a0;using accepted criteria, a referral to a rheumatologic specialist may be indicated, particularly in those with positive HLA-B27 testing and confirmation of sacroiliitis&#x000a0;by imaging. In addition, a physical therapy referral is likely warranted as&#x000a0;IBP and its associated inflammatory illnesses&#x000a0;have shown&#x000a0;favorable responses to exercise and movement therapies.&#x000a0;This multidisciplinary approach aims to optimize patient outcomes and enhance overall well-being.</p>
      </sec>
      <sec id="article-23508.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The initial&#x000a0;intervention for patients with&#x000a0;IBP should begin with education, providing insights into the&#x000a0;anticipated course of&#x000a0;the condition and emphasizing the need for further evaluation&#x000a0;to identify potential sources of the inflammatory process. Patients should be advised to cease smoking, as it may exacerbate symptoms, and they should receive referrals to sources of psychosocial support. Notably, physical therapy, focusing on exercise and postural training, is an essential component of the treatment plan, as these interventions can offer significant benefits in managing the course of the disease.<xref ref-type="bibr" rid="article-23508.r19">[19]</xref></p>
      </sec>
      <sec id="article-23508.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>A few key facts to remember about IBP are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Timely recognition of IBP is crucial for initiating appropriate interventions and preventing complications associated with spondyloarthropathies.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Regular monitoring of patients with IBP, including imaging and laboratory assessments, helps track disease progression and modify treatment strategies accordingly.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Encouraging patients to adopt a healthy lifestyle, including regular exercise and smoking cessation, can contribute to symptom control and overall well-being.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Screening individuals in high-risk groups, such as those with a family history or specific genetic markers, may aid in the early detection of IBP.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A multidisciplinary approach involving rheumatologists, primary care providers, physical therapists, and other specialists enhances the overall management of IBP.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Genetic factors, including the presence of HLA-B27, play a significant role in developing IBP. Understanding genetic predispositions can guide diagnostic and management strategies.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23508.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing IBP requires clinical skills, strategic planning, ethical considerations, shared responsibilities, effective communication, and coordinated care. An interprofessional team approach is paramount for optimizing patient outcomes and enhancing the overall quality of care.&#x000a0;Collaborative responsibilities among healthcare professionals, including rheumatologists, primary care providers, nurses, therapists, and pharmacists, are integral to effectively managing IBP.</p>
        <p>Healthcare professionals are responsible for educating patients about the nature of IBP, treatment options, potential complications, and the importance of lifestyle modifications. Interprofessional communication should support shared decision-making, involving patients in discussions about their care and treatment options.</p>
      </sec>
      <sec id="article-23508.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23508&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23508">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/inflammatory-back-pain/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23508">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23508/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23508">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23508.s18">
        <title>References</title>
        <ref id="article-23508.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Holme</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Insights into the pathogenesis of axial spondyloarthropathy from network and pathway analysis.</article-title>
            <source>BMC Syst Biol</source>
            <year>2012</year>
            <volume>6 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S4</fpage>
            <pub-id pub-id-type="pmid">23046677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chyuan</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies.</article-title>
            <source>Mediators Inflamm</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>2403935</fpage>
            <pub-id pub-id-type="pmid">29670461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weisman</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory back pain: the United States perspective.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>501</fpage>
            <page-range>501-12</page-range>
            <pub-id pub-id-type="pmid">23083751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>1264</fpage>
            <page-range>1264-8</page-range>
            <pub-id pub-id-type="pmid">20566619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pettit</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Weedon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Expression profiling in spondyloarthropathy synovial biopsies highlights changes in expression of inflammatory genes in conjunction with tissue remodelling genes.</article-title>
            <source>BMC Musculoskelet Disord</source>
            <year>2013</year>
            <month>Dec</month>
            <day>15</day>
            <volume>14</volume>
            <fpage>354</fpage>
            <pub-id pub-id-type="pmid">24330574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamilton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Macgregor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Warmington</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pinch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gaffney</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The prevalence of inflammatory back pain in a UK primary care population.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>161</fpage>
            <page-range>161-4</page-range>
            <pub-id pub-id-type="pmid">24136063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lau</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Gun</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Yeap</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mohd Zain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohd Yusoof</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sargunan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yahya</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Algorithm for the referral of patients with inflammatory back pain from primary care in Malaysia.</article-title>
            <source>Malays Fam Physician</source>
            <year>2021</year>
            <month>Jul</month>
            <day>22</day>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>2</fpage>
            <page-range>2-6</page-range>
            <pub-id pub-id-type="pmid">34386157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tam</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baek</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Chiowchanwisawakit</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dans</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hagino</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kishimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Soroosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stebbings</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yeap</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>2018 APLAR axial spondyloarthritis treatment recommendations.</article-title>
            <source>Int J Rheum Dis</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>340</fpage>
            <page-range>340-356</page-range>
            <pub-id pub-id-type="pmid">30816645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Parameswaran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lucke</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>HLA-B27 Syndromes</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">31855367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taurog</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Croft</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Sueiro</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Balish</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hammer</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats.</article-title>
            <source>J Exp Med</source>
            <year>1994</year>
            <month>Dec</month>
            <day>01</day>
            <volume>180</volume>
            <issue>6</issue>
            <fpage>2359</fpage>
            <page-range>2359-64</page-range>
            <pub-id pub-id-type="pmid">7964509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiwana</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Natt</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Benitez-Brito</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bridger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harbord</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ebringer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Correlation between the immune responses to collagens type I, III, IV and V and Klebsiella pneumoniae in patients with Crohn's disease and ankylosing spondylitis.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-23</page-range>
            <pub-id pub-id-type="pmid">11157137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Thatayatikom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Modica</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Leucio</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Juvenile Idiopathic Arthritis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">32119492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ajene</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Fischer Walker</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis.</article-title>
            <source>J Health Popul Nutr</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-307</page-range>
            <pub-id pub-id-type="pmid">24288942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baeten</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kruithof</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Rycke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boots</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mielants</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Veys</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>De Keyser</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2005</year>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>R359</fpage>
            <page-range>R359-69</page-range>
            <pub-id pub-id-type="pmid">15743484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandt</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Spiller</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Vahldiek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rudwaleit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sieper</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>66</volume>
            <issue>11</issue>
            <fpage>1479</fpage>
            <page-range>1479-84</page-range>
            <pub-id pub-id-type="pmid">17456526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rudwaleit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Landew&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Listing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Akkoc</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brandt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Collantes-Estevez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kirazli</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Maksymowych</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Mielants</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Ozgocmen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roussou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Valle-O&#x000f1;ate</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sieper</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>777</fpage>
            <page-range>777-83</page-range>
            <pub-id pub-id-type="pmid">19297344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical study of Tongdu Shujin decoction in the treatment of ankylosing spondylitis with cold-dampness obstruction type: Study protocol for a randomized controlled trial.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2023</year>
            <month>Feb</month>
            <day>10</day>
            <volume>102</volume>
            <issue>6</issue>
            <fpage>e32852</fpage>
            <pub-id pub-id-type="pmid">36820580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Aboobacker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Al Aboud</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <chapter-title>Secukinumab</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30725776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Landew&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baraliakos</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Van den Bosch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sepriano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Regel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ciurea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dagfinrud</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Gaalen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>G&#x000e9;her</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Horst-Bruinsma</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Jongkees</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiltz</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Marzo-Ortega</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Molto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navarro-Comp&#x000e0;n</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ozgocmen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pimentel-Santos</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Reveille</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rudwaleit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sieper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sampaio-Barros</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>978</fpage>
            <page-range>978-991</page-range>
            <pub-id pub-id-type="pmid">28087505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;ls</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gladman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Landew&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mease</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sieper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stamm</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aletaha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baraliakos</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Betteridge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>FVD</given-names>
              </name>
              <name>
                <surname>Coates</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gensler</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Gossec</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Helliwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jongkees</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Maccarone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Molto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ogdie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poddubnyy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ritchlin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rudwaleit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanew</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thio</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Veale</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vlam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-17</page-range>
            <pub-id pub-id-type="pmid">28684559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Malik</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Aurelio</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <chapter-title>Extraintestinal Manifestations of Inflammatory Bowel Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">33760556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wahl</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sesto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boissonnault</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Differential diagnosis of a patient with low back and toe pain.</article-title>
            <source>J Man Manip Ther</source>
            <year>2013</year>
            <month>May</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-9</page-range>
            <pub-id pub-id-type="pmid">24421618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhagen</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Downie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Koes</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Most red flags for malignancy in low back pain guidelines lack empirical support: a systematic review.</article-title>
            <source>Pain</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>158</volume>
            <issue>10</issue>
            <fpage>1860</fpage>
            <page-range>1860-1868</page-range>
            <pub-id pub-id-type="pmid">28708761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>C&#x000f4;t&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Randhawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Varatharajan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldgrub</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nordin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Shearer</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ameis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Southerst</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mior</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stupar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Varatharajan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taylor-Vaisey</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice guidelines for the noninvasive management of low back pain: A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration.</article-title>
            <source>Eur J Pain</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>201</fpage>
            <page-range>201-216</page-range>
            <pub-id pub-id-type="pmid">27712027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kroon</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>van der Burg</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Ramiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Landew&#x000e9;</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Buchbinder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Falzon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Jul</month>
            <day>17</day>
            <volume>2015</volume>
            <issue>7</issue>
            <fpage>CD010952</fpage>
            <pub-id pub-id-type="pmid">26186173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of axial spondyloarthritis: an update.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-143</page-range>
            <pub-id pub-id-type="pmid">29227352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaudhary</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Hullinger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vives</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Management of acute spinal fractures in ankylosing spondylitis.</article-title>
            <source>ISRN Rheumatol</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>150484</fpage>
            <pub-id pub-id-type="pmid">22389792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molt&#x000f3;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Etcheto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Landew&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van den Bosch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bautista Molano</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Burgos-Vargas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Collantes-Estevez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Deodhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El-Zorkany</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Erdes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hajjaj-Hassouni</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kiltz</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Kishimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Maksymowych</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Maldonado-Cocco</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marzo-Ortega</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Montecucco</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ozgo&#x000e7;men</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Gaalen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1016</fpage>
            <page-range>1016-23</page-range>
            <pub-id pub-id-type="pmid">26489703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mundwiler</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Siddique</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dym</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Perri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Weisman</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Complications of the spine in ankylosing spondylitis with a focus on deformity correction.</article-title>
            <source>Neurosurg Focus</source>
            <year>2008</year>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>E6</fpage>
            <pub-id pub-id-type="pmid">18290744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>HI</given-names>
              </name>
            </person-group>
            <article-title>Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker.</article-title>
            <source>Rheumatol Int</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>1689</fpage>
            <page-range>1689-92</page-range>
            <pub-id pub-id-type="pmid">23269570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Biasucci</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.</article-title>
            <source>Postgrad Med</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>130</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-71</page-range>
            <pub-id pub-id-type="pmid">29202670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23508.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shim</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>[Nonsteroidal Anti-inflammatory Drug and Aspirin-induced Peptic Ulcer Disease].</article-title>
            <source>Korean J Gastroenterol</source>
            <year>2016</year>
            <month>Jun</month>
            <day>25</day>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>300</fpage>
            <page-range>300-12</page-range>
            <pub-id pub-id-type="pmid">27312830</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
